Revolution Medicines, Inc.

Good day, and thank you for standing by. Welcome to the Revolution Medicine's Q1 2026 earnings call. At this time, participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone. You will then hear an automated message advising you your hand is raised. To withdraw your question, please press star 1 1 again. Please be advised that today's conference is being recorded. I would now like to hand it over to Ryan A.C., Senior VP of Corporate Affairs. Ryan, you have the floor.

Thank you, operator, and welcome everyone to the first quarter 2026 earnings call. Joining me on today's call are Dr. Mark Goldsmith, Revolution Medicine's Chairman and Chief Executive Officer, Dr. Alan Sandler, our Chief Development Officer, and Jack Anders, our Chief Financial Officer. Dr. Steve Kelsey, our president of R&D, Dr. Wei Lin, our chief medical officer, and Anthony Mancini, our chief global commercialization officer, will join us for the Q&A portion of today's call. We would like to inform you that certain statements we made during this call will be forward-looking because such statements deal with future events and are subject to many risks and uncertainties. Actual results may differ maturely from those in forward-looking statements. For a full discussion of these risks and uncertainties, Please review our annual report on Form 10-K and our quarterly report on Form 10-Q that are filed at the U.S. Securities and Exchange Commission. This afternoon, we released financial results for the quarter ended March 31st, 2026 and recent corporate updates. The press release and updated corporate presentation are available on the investor section of our website at RevMed.com. With that, I'll turn the call over to Dr. Mark Goldsmith, Revolution Medicine's Chairman and Chief Executive Officer.

Mark?